TOP NEWS: GSK reaches settlement in California Zantac lawsuit
23rd Jun 2023 08:23
(Alliance News) - GSK PLC on Friday said a Zantac trial set to begin next month in California has been dismissed after it reached a confidential settlement. Read More
(Alliance News) - GSK PLC on Friday said a Zantac trial set to begin next month in California has been dismissed after it reached a confidential settlement. Read More
(Alliance News) - Stocks in London are set to open in the red on Friday, as risk sentiment across the globe is damped by hawkish central banks. Read More
(Alliance News) - GSK PLC on Thursday said the US Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices has voted to recommend the firm's Arexvy jab in adults aged 60 and older. Read More
(Alliance News) - GSK PLC on Wednesday reported positive data for Arexvy, its respiratory syncytial virus vaccine for older adults. Read More
(Alliance News) - Stocks in London ended largely higher on Friday, following a busy week centred on the interest rate decisions of three major central banks. Read More
(Alliance News) - GSK PLC must gain approval for its "centrepiece" cancer drug momelotinib to validate its mergers & acquisitions pipeline but the extension of its review period in the US does not automatically spell trouble, according to analysis from Shore Capital on Friday. Read More
GSK PLC - Brentford, England-based pharmaceutical company - Says US Food & Drug Administration has extended the review period of the new drug application for momelotinib by three months. Extension aims to provide time to review recently submitted data. The extended action date is September 16. Momelotinib uses "novel mechanism of action" to treat myelofibrosis, a rare blood cancer, as well as progressive anaemia which characterises the disease. Myelofibrosis affects approximately 25,000 US patients. The drug is not currently approved in any markets. GSK says it is "confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review." Read More
(Alliance News) - AstraZeneca PLC on Thursday said that a US Food & Drug Administration committee unanimously recommended its antibody nirsevimab. Read More
(Alliance News) - A recent revival of initial public offerings in London's equity markets is encouraging evidence that the city still holds appeal on the global stage, analysts contended. Read More
(Alliance News) - Stock prices in London opened in the red on Wednesday, as concerns about interest rate hikes and a global economic slowdown damped risk appetite. Read More
(Alliance News) - GSK PLC on Wednesday announced that its RSV vaccine Arexvy has become the first EU-backed vaccine against the respiratory syncytial virus for adults aged 60 and older. Read More
(Alliance News) - GSK PLC on Tuesday said the US Food & Drug Administration accepted its supplemental biologics licence application for endometrial cancer treatment dostarlimab, or Jemperli, after it was granted priority review in September. Read More
(Alliance News) - Unilever PLC has appointed executive search firm Spencer Stuart to find a replacement for Chair Nils Andersen, Bloomberg reported on Monday, citing "people familiar with the situation". Read More
(Alliance News) - hVIVO's involvement in the approval of pharmaceutical giant Pfizer's new vaccine Abrysvo should support interest in its services, according to Liberum. Read More
Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Chief Executive Officer Neil Clark steps down immediately "to pursue new challenges". Clark will "support [Destiny] for a limited period to ensure an orderly handover." Non-Executive Director Debra Barker will serve as interim CEO until Destiny appoints a permanent replacement. Barker has held "key roles" at Novartis AG and Polyphor AG, now named Spexis AG. She also has previously worked at Roche Holding AG, Polyneuron Pharmaceuticals AG and GSK PLC. Read More
(Alliance News) - Stocks in London ended the week broadly higher on Friday, with strong performances from blue-chips Beazley and GSK helping to offset weak economic growth data for the UK economy. Read More
(Alliance News) - Stock prices in London were mixed at midday on Friday as investors digested a weak GDP reading for the UK, a day after the Bank of England took the country's interest rates up to a 15-year-high. Read More
(Alliance News) - GSK PLC on Friday reported positive preliminary results from a phase 3 trial regarding its 5-in-1 meningococcal ABCWY vaccine candidate. Read More
(Alliance News) - GSK PLC on Friday welcomed a legal ruling in Canada that threw out a proposed class action made on behalf of users of a heartburn drug. Read More
(Alliance News) - Stocks in London were called to open higher on Friday, after data showed the UK economy expanded 0.1% over the first three months of the year. Read More